<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="159762">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01910194</url>
  </required_header>
  <id_info>
    <org_study_id>LanLyx</org_study_id>
    <nct_id>NCT01910194</nct_id>
  </id_info>
  <brief_title>Impact of Combined of Lantus(Insulin Glargine) and Lyxumia (Lixisenatide) on Insulin Secretion and Gastric Emptying</brief_title>
  <official_title>A Bicentric Open-label, Randomized, Two-parallel-group Study Investigating the Impact of Combined Lantus Insulin Glargine) and Lyxumia(Lixisenatide) on Insulin Secretion and Gastric Emptying in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled on Diet and Oral Antidiabetic Medication</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Profil Institut für Stoffwechselforschung GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Profil Institut für Stoffwechselforschung GmbH</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Impact of combined Lantus (insulin glargine) and Lyxumia(lixisenatide) on insulin secretion
      and gastric emptying
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Impact of combined Lantus (insulin glargine) and Lyxumia(lixisenatide) on insulin secretion
      and gastric emptying
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>AUCISEC(0-10min)</measure>
    <time_frame>Within 0 to 10 min after iv glucose challenge</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Lyxumia</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>4 weeks Luxumia plus another 4 weeks combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lantus</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>4 weeks Lantus plus another 4 weeks combination</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Luyxumia  versus Lantus</intervention_name>
    <arm_group_label>Lyxumia</arm_group_label>
    <arm_group_label>Lantus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with type 2 diabetes mellitus diagnosed at least one year before the
             screening visit not previously treated with glitazones, insulin or GLP-1 agonists

          -  Inadequately controlled diabetes mellitus

        Exclusion Criteria:

          -  Subjects with type 1 diabetes, maturity onset diabetes of the young (MODY) or
             secondary forms of diabetes such as due to pancreatitis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Juris J Meier, MD</last_name>
    <phone>+49234509</phone>
    <phone_ext>2711</phone_ext>
    <email>juris.meier@rub.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Josef-Hospital, University Hospital, Ruhr</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juris J Meier, MD</last_name>
      <phone>+49234509</phone>
      <phone_ext>2711</phone_ext>
      <email>juris.meier@rub.de</email>
    </contact>
    <investigator>
      <last_name>Juris J Meier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Profil Institut für Stoffwechselforschung GmbH</name>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Kapitza, MD</last_name>
      <phone>+4921314018</phone>
      <phone_ext>145</phone_ext>
      <email>regulatory@profil.com</email>
    </contact>
    <investigator>
      <last_name>Christoph Kapitza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>February 4, 2014</lastchanged_date>
  <firstreceived_date>July 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glargine</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
